Sionna Therapeutics, Inc. financial data

Symbol
SION on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 02 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2676% %
Debt-to-equity 5.3% %
Return On Equity -23% % -153%
Return On Assets -22% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44,998,073 shares 2%
Common Stock, Shares, Outstanding 44,723,585 shares 847%
Common Stock, Value, Issued $45,000 USD 800%
Weighted Average Number of Shares Outstanding, Basic 39,962,163 shares 936%
Weighted Average Number of Shares Outstanding, Diluted 39,962,163 shares 936%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $60,263,000 USD 5.2%
General and Administrative Expense $28,719,000 USD 116%
Operating Income (Loss) $88,982,000 USD -26%
Nonoperating Income (Expense) $13,714,000 USD 55%
Net Income (Loss) Attributable to Parent $75,268,000 USD -22%
Earnings Per Share, Basic -1.88 USD/shares 88%
Earnings Per Share, Diluted -1.88 USD/shares 88%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $58,451,000 USD 55%
Cash, Cash Equivalents, and Short-term Investments $325,000,000 USD
Assets, Current $241,419,000 USD 60%
Property, Plant and Equipment, Net $2,225,000 USD -9.8%
Operating Lease, Right-of-Use Asset $6,926,000 USD -12%
Other Assets, Noncurrent $0 USD -100%
Assets $325,953,000 USD 75%
Employee-related Liabilities, Current $4,740,000 USD 59%
Accrued Liabilities, Current $9,668,000 USD 18%
Liabilities, Current $11,712,000 USD 12%
Operating Lease, Liability, Noncurrent $7,408,000 USD -15%
Liabilities $19,120,000 USD 0.12%
Accumulated Other Comprehensive Income (Loss), Net of Tax $540,000 USD 47%
Retained Earnings (Accumulated Deficit) $256,354,000 USD -42%
Stockholders' Equity Attributable to Parent $306,833,000 USD
Liabilities and Equity $325,953,000 USD 75%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 500,000,000 shares 806%
Common Stock, Shares, Issued 44,723,585 shares 832%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $59,414,000 USD 53%
Deferred Tax Assets, Valuation Allowance $76,144,000 USD 48%
Deferred Tax Assets, Gross $78,120,000 USD 45%
Operating Lease, Liability $8,677,000 USD
Depreciation $647,000 USD -3.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $75,096,000 USD -22%
Lessee, Operating Lease, Liability, to be Paid $11,394,000 USD
Property, Plant and Equipment, Gross $4,347,000 USD 7.7%
Operating Lease, Liability, Current $1,269,000 USD 18%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,253,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $2,190,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,717,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,319,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $40,906,000 USD 126%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,386,000 USD
Additional Paid in Capital $562,602,000 USD 3209%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $1,976,000 USD -8.7%
Share-based Payment Arrangement, Expense $12,066,000 USD 225%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%